Awarded: Jan 01, 2009
$2,430,000 over 3 years
In 2009, the foundation awarded three-year grants of $486,000 each to five early-stage research projects that have the potential to catalyze innovative therapies for sickle cell disease.
2009 ICRA Grantees
James E. Bradner, M.D.
Dana-Farber Cancer Institute
Project name: Selective Inhibition of HDAC1 and HDAC2 in Sickle Cell Disease
Michael M. Dowling, M.D., Ph.D.
University of Texas Southwestern Medical Center at Dallas
Project name: PFAST: Patent Foramen Ovale and Stroke in Sickle Cell Disease
Benjamin L. Ebert, M.D., Ph.D., and Maureen Okam, M.D., M.P.H.
Brigham and Women's Hospital
Project name: Clinical Development of Histone Deacetylase Inhibitors for the Treatment of Sickle Cell Disease
Donald B. Kohn, M.D., and Philip Gregory, Ph.D.
University of California, Los Angeles, and Sangamo Biosciences, Inc.
Project name: ß-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease
Guillaume Lettre, Ph.D., and Joel N. Hirschhorn, M.D., Ph.D.
Montreal Heart Institute and Children's Hospital Boston
Project name: Whole-exome Re-sequencing in Sickle Cell Disease Patients with Extremely Mild Clinical Courses